JAMA Network Home
Sign In
Research Letter

Darolutamide With Concomitant Lipid-Modifying Agents in Nonmetastatic Castration-Resistant Prostate Cancer

JAMA Network Open 10.1001/jamanetworkopen.2026.29936

August 19, 2026 at 11:00 AM EDT

Read the full article

This nonrandomized clinical trial assesses the safety and efficacy of darolutamide, with or without concomitant lipid-modifying agents (LMAs), in treating nonmetastatic castration-resistant prostate cancer.

Corresponding Author: Murilo A. Luz, MD, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Pl, New York, NY 10029 (muriloaluz@gmail.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.29936?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=081926

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks